1. Αρχική σελίδα
  2. Αναζήτηση

Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis

Το τεκμήριο παρέχεται από τον φορέα :
Ελληνική Γαστροεντερολογική Εταιρία   

Αποθετήριο :
Annals of Gastroenterology   

δείτε την πρωτότυπη σελίδα τεκμηρίου
στον ιστότοπο του αποθετηρίου του φορέα για περισσότερες πληροφορίες και για να δείτε όλα τα ψηφιακά αρχεία του τεκμηρίου*



Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis (EN)
Katsoula, Anastasia
Tsapas, Apostolos
Liakos, Aris
Sarigianni, Maria
Paschos, Paschalis
Giouleme, Olga
Athanasiadou, Eleni
Bekiari, Eleni
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
2018-08-23
Background The aim of the study was to assess the efficacy and safety of tofacitinib and its impacton quality of life in patients with moderate-to-severe ulcerative colitis. Methods We conducted a systematic review and meta-analysis of randomized controlledtrials comparing tofacitinib with placebo or any active comparator. We searched Medline,Embase, the Cochrane Library and gray literature for articles published up to May 2017.We synthesized data using a fixed-effect model. We conducted subgroup analysis based onprior exposure to anti-tumor necrosis factor (TNF). We summarized the strength of evidenceusing the Grading of Recommendations Assessment, Development and Evaluation (GRADE)approach. Results We included three trials with 1220 participants. Compared with placebo, tofacitinib waseffective in inducing clinical remission (odds ratio [OR] 3.84, 95% confidence interval [CI] 2.29-6.44, I2: 41%, GRADE: moderate), clinical response (OR 2.95, 95%CI 2.21-3.95, I2: 0%, GRADE:high), mucosal healing (OR 2.70, 95%CI 1.81-4.03, I2: 0%, GRADE: high). Tofacitinib was effectivein both anti-TNF-naïve and -experienced patients. Tofacitinib had a favorable effect on qualityof life. There were no significant differences in the safety profile in terms of the incidence of anyor serious adverse events compared to placebo. The risk for infections was increased (OR 1.51,95%CI 1.05-2.19, I2: 0%, GRADE: moderate), but the incidence of serious infections did not differbetween tofacitinib and placebo. Conclusion In patients with moderate-to-severe ulcerative colitis, short-term treatment withtofacitinib is effective for induction of remission and improvement of quality of life. Keywords Tofacitinib, ulcerative colitis, meta-analysis Ann Gastroenterol 2018; 31 (5): 572-582 (EN)
Αγγλική γλώσσα
Hellenic Society of Gastroenterology (EN)
1792-7463
1108-7471
Annals of Gastroenterology; Volume 31, No 5 (2018); 572 (EN)
Copyright (c) 2018 Annals of Gastroenterology (EN)
Ελληνική Γαστροεντερολογική Εταιρία
Annals of Gastroenterology
Original Articles



*Η εύρυθμη και αδιάλειπτη λειτουργία των διαδικτυακών διευθύνσεων των συλλογών (ψηφιακό αρχείο, καρτέλα τεκμηρίου στο αποθετήριο) είναι αποκλειστική ευθύνη των αντίστοιχων Φορέων περιεχομένου.